Literature DB >> 33419479

The views of health guideline developers on the use of automation in health evidence synthesis.

Anneliese Arno1, Julian Elliott2, Byron Wallace3, Tari Turner2, James Thomas4.   

Abstract

BACKGROUND: The increasingly rapid rate of evidence publication has made it difficult for evidence synthesis-systematic reviews and health guidelines-to be continually kept up to date. One proposed solution for this is the use of automation in health evidence synthesis. Guideline developers are key gatekeepers in the acceptance and use of evidence, and therefore, their opinions on the potential use of automation are crucial.
METHODS: The objective of this study was to analyze the attitudes of guideline developers towards the use of automation in health evidence synthesis. The Diffusion of Innovations framework was chosen as an initial analytical framework because it encapsulates some of the core issues which are thought to affect the adoption of new innovations in practice. This well-established theory posits five dimensions which affect the adoption of novel technologies: Relative Advantage, Compatibility, Complexity, Trialability, and Observability. Eighteen interviews were conducted with individuals who were currently working, or had previously worked, in guideline development. After transcription, a multiphase mixed deductive and grounded approach was used to analyze the data. First, transcripts were coded with a deductive approach using Rogers' Diffusion of Innovation as the top-level themes. Second, sub-themes within the framework were identified using a grounded approach.
RESULTS: Participants were consistently most concerned with the extent to which an innovation is in line with current values and practices (i.e., Compatibility in the Diffusion of Innovations framework). Participants were also concerned with Relative Advantage and Observability, which were discussed in approximately equal amounts. For the latter, participants expressed a desire for transparency in the methodology of automation software. Participants were noticeably less interested in Complexity and Trialability, which were discussed infrequently. These results were reasonably consistent across all participants.
CONCLUSIONS: If machine learning and other automation technologies are to be used more widely and to their full potential in systematic reviews and guideline development, it is crucial to ensure new technologies are in line with current values and practice. It will also be important to maximize the transparency of the methods of these technologies to address the concerns of guideline developers.

Entities:  

Keywords:  Automation; Diffusion of Innovation; Evidence synthesis; Guideline development; Machine learning; Systematic reviews

Mesh:

Year:  2021        PMID: 33419479      PMCID: PMC7796617          DOI: 10.1186/s13643-020-01569-2

Source DB:  PubMed          Journal:  Syst Rev        ISSN: 2046-4053


  11 in total

1.  How quickly do systematic reviews go out of date? A survival analysis.

Authors:  Kaveh G Shojania; Margaret Sampson; Mohammed T Ansari; Jun Ji; Steve Doucette; David Moher
Journal:  Ann Intern Med       Date:  2007-07-16       Impact factor: 25.391

2.  Usage of automation tools in systematic reviews.

Authors:  A J van Altena; R Spijker; S D Olabarriaga
Journal:  Res Synth Methods       Date:  2019-01-22       Impact factor: 5.273

3.  The automation of systematic reviews.

Authors:  Guy Tsafnat; Adam Dunn; Paul Glasziou; Enrico Coiera
Journal:  BMJ       Date:  2013-01-10

Review 4.  Patient and Public Involvement in the Development of Healthcare Guidance: An Overview of Current Methods and Future Challenges.

Authors:  Ahmed Rashid; Victoria Thomas; Toni Shaw; Gillian Leng
Journal:  Patient       Date:  2017-06       Impact factor: 3.883

5.  Seventy-five trials and eleven systematic reviews a day: how will we ever keep up?

Authors:  Hilda Bastian; Paul Glasziou; Iain Chalmers
Journal:  PLoS Med       Date:  2010-09-21       Impact factor: 11.069

6.  Usability and acceptability of four systematic review automation software packages: a mixed method design.

Authors:  Gina Cleo; Anna Mae Scott; Farhana Islam; Blair Julien; Elaine Beller
Journal:  Syst Rev       Date:  2019-06-20

7.  Still moving toward automation of the systematic review process: a summary of discussions at the third meeting of the International Collaboration for Automation of Systematic Reviews (ICASR).

Authors:  Annette M O'Connor; Guy Tsafnat; Stephen B Gilbert; Kristina A Thayer; Ian Shemilt; James Thomas; Paul Glasziou; Mary S Wolfe
Journal:  Syst Rev       Date:  2019-02-20

8.  Toward systematic review automation: a practical guide to using machine learning tools in research synthesis.

Authors:  Iain J Marshall; Byron C Wallace
Journal:  Syst Rev       Date:  2019-07-11

9.  Living systematic reviews: 2. Combining human and machine effort.

Authors:  James Thomas; Anna Noel-Storr; Iain Marshall; Byron Wallace; Steven McDonald; Chris Mavergames; Paul Glasziou; Ian Shemilt; Anneliese Synnot; Tari Turner; Julian Elliott
Journal:  J Clin Epidemiol       Date:  2017-09-11       Impact factor: 6.437

10.  Living systematic reviews: an emerging opportunity to narrow the evidence-practice gap.

Authors:  Julian H Elliott; Tari Turner; Ornella Clavisi; James Thomas; Julian P T Higgins; Chris Mavergames; Russell L Gruen
Journal:  PLoS Med       Date:  2014-02-18       Impact factor: 11.069

View more
  2 in total

1.  Automating risk of bias assessment in systematic reviews: a real-time mixed methods comparison of human researchers to a machine learning system.

Authors:  Patricia Sofia Jacobsen Jardim; Christopher James Rose; Heather Melanie Ames; Jose Francisco Meneses Echavez; Stijn Van de Velde; Ashley Elizabeth Muller
Journal:  BMC Med Res Methodol       Date:  2022-06-08       Impact factor: 4.612

2.  Guidance for using artificial intelligence for title and abstract screening while conducting knowledge syntheses.

Authors:  Candyce Hamel; Mona Hersi; Shannon E Kelly; Andrea C Tricco; Sharon Straus; George Wells; Ba' Pham; Brian Hutton
Journal:  BMC Med Res Methodol       Date:  2021-12-20       Impact factor: 4.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.